News from IAS 2007

• IAS: Maraviroc produces best results when combined with another active drug
• IAS: Boosted atazanavir shows edge over unboosted in treatment-naive after 96 weeks
• IAS: HPV diversity suggests value of HIV-positive gay men receiving <i>Gardasil</i>
• IAS: Poor adherence and virological outcomes in children receiving HIV care in rural Uganda
• IAS: Incidence of some cancers increasing significantly in HIV-positive individuals
• IAS: How can HIV testing be expanded while protecting individual rights?
• IAS: Diagnosis during primary infection reduces risky sex
• IAS: Atazanavir safe and effective in HCV-coinfected patients with cirrhosis
• IAS: Rectal trauma and drug use key in sexual transmission of HCV
• IAS: HCV therapy does not significantly effect immune recovery of patients taking HIV therapy
• IAS: Aging with HIV - are cancer, heart disease, dementia the new challenges?
• IAS: Pendulum swinging towards early treatment as burden of pre-AIDS illness recognised
• IAS: Roche admits long-standing low-level contamination of nelfinavir
• IAS: <i>Truvada</i> more effective than <i>Kivexa</i> due to drop-outs related to abacavir hypersensitivity
• IAS: Early treatment of HIV-infected infants with ART significantly reduces mortality
• IAS: Cellulose sulphate microbicide fails to prevent vaginal HIV transmission – and may even increase risk
• IAS: Regular dietician consultation effective at preventing HAART-associated dyslipidaemia
• IAS: Circumcision may be acceptable to some gay men, but study says no value for HIV prevention
• IAS: Penile washing after sex not a substitute for circumcision
• IAS: Models predict costs and benefits of circumcision programmes
• IAS: Screening for B*5701 reduces abacavir hypersensitivity incidence to zero
• IAS: Maraviroc slightly less effective but more tolerable in treatment-naive patients
• IAS: Lack of data on men with weak immune systems weakens study comparing safety of circumcision in HIV-positive and HIV-negative men
• IAS: Cardiovascular disease and diabetes increasing as causes of death for people with HIV in Brazil
• IAS: Low rates of HIV transmission in breastfeeding women on ART
• IAS: ART interruption particularly unsafe for HIV-positive patients coinfected with hepatitis B or C
• IAS: Novel once-daily CCR5 antagonist, INC9471, appears potent, well tolerated after 14 days monotherapy
• IAS: Hepatitis C clusters reveal international transmission among HIV-positive gay men
• IAS: Integrase inhibitor raltegravir (MK-0518) potent, durable and more tolerable than efavirenz in treatment-naive at 48 weeks
• IAS: Aciclovir treatment doesn't significantly reduce HIV or HSV-2 shedding in genital secretions